# Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

> **NCT01182350** · PHASE2 · TERMINATED · sponsor: **Karen D. Wright MD** · enrollment: 53 (actual)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Erlotinib
- **DRUG:** Temozolomide
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT01182350
- **Lead sponsor:** Karen D. Wright MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** Per design: Stop if fewer than 3 cohorts by molecular classification were with 10 participants or only 1 cohort enrolled at least 15 participants of 50.
- **Last updated:** 2019-09-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01182350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01182350, "Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01182350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*